Printer Friendly

SAFETY TESTING OF AIDS VACCINE COMPLETED

 SAFETY TESTING OF AIDS VACCINE COMPLETED
 BETHESDA, Md., July 24 /PRNewswire/ -- CEL-SCI Corporation


(NASDAQ: CELI) and Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), announced that the first phase of human testing of HGP-30, an AIDS vaccine, in healthy HIV-negative volunteers has been completed and is reported in the summer issue of Vaccine Research. In the paper, the researchers reported that 18 healthy volunteers safely tolerated the vaccine with no evidence of significant chemical or hematologic toxicity attributable to the vaccine for periods of up to one year. The trial was conducted at the Kobler AIDS Center, St. Stephen's Hospital, London, by Brian Gazzard, M.D., in collaboration with an international team of scientists from England, the United States and France.
 Allan L. Goldstein, Ph.D., professor and chairman of the Department of Biochemistry and Molecular Biology at the George Washington University Medical Center, is head of the U.S. team that developed the vaccine. Goldstein noted: "The team was encouraged by the fact that the vaccine was safely tolerated. Some individuals showed T-cell responses including the ability to elicit cytotoxic 'killer' T-cells that are thought to be essential in the elimination of AIDS infected cells."
 The vaccine was shown to elicit antibodies to HGP-30 in 17 of 18 volunteers and stimulate the production of HGP-30 specific T-cells in five of nine volunteers tested.
 Goldstein indicated that, although these results are preliminary, they suggest that further human studies utilizing HGP-30 appear warranted, and that the core protein of the AIDS virus could be important in the development of a successful vaccine.
 The HGP-30-based vaccine is designed to overcome one of the major barriers to successful AIDS vaccine development. HGP-30 is a synthetic copy of a region of the p17 core protein of the AIDS virus. Unlike the envelope of the AIDS virus which undergoes frequent genetic change, this core region is highly conserved from strain to strain.
 The London study is the first vaccine trial anywhere in the world to use a synthetic peptide subunit of HIV-1 as the active component. The data reported indicated that HGP-30 is recognized by the immune system and can induce the formation of cytotoxic T-cells which are essential for the destruction of virally infected cells. This observation is particularly noteworthy because the T-cells that are produced appear to be a type of cell termed "CD8+" cytotoxic T-cells, that, until this study, were not thought to be inducible by small soluble peptides such as HGP-30. CD8+ cytotoxic cells are thought to be vital for the development of an effective AIDS vaccine.
 The patented rights to the HGP-30 AIDS vaccine are owned by Viral Technologies, Inc., a joint venture of CEL-SCI Corporation and Alpha 1 Biomedicals, Inc.
 -0- 7/24/92
 /CONTACT: Vincent F. Simmon, Ph.D., Alpha 1 Biomedicals, 301-564-4400; or Geert Kersten of CEL-SCI, 703-549-5293/
 (CELI ALBM) CO: CEL-SCI Corporation; Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:


TW -- DC001 -- 2903 07/24/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 24, 1992
Words:492
Previous Article:PNC, FIRST NATIONAL PENNSYLVANIA MERGER CLOSES
Next Article:NATIONSBANK TO HOLD CELEBRATION FOR OPENING OF SUMMER OLYMPIC GAMES
Topics:


Related Articles
NEW HUMAN STUDIES BEGIN WITH AIDS VACCINE CANDIDATE HGP-30
CEL-SCI CORPORATION Announces Interim Results of HGP-30 AIDS Vaccine Study
FDA OKS TESTS OF PREVENTIVE AIDS VACCINE.
FDA Approves St. Jude Safety Trial for Second Part of Three-part Vaccine To Prevent AIDS.
IAVI Hails Start of Trial in South Africa and U.S. to Test AlphaVax's AIDS Vaccine.
South Africa Approves IAVI Sponsored AIDS Vaccine Candidate for Human Trials.
IAVI Begins AIDS Vaccine Trials in South Africa, Switzerland.
GENVAC VACCINE ENTERS HIV HUMAN THERAPEUTIC CLINICAL TRIALS.
GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters